Nektar Therapeutics Targets December for Phase 3 Alopecia Trial as REZPEG Advances

Nektar Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Nektar expects to start a Phase 3 REZPEG trial for alopecia areata in December, enrolling 850 patients aged 12 and older; results are expected in 2029. The company says Phase 2 patients largely maintained or continued hair regrowth during six months off treatment.
  • Three Phase 3 trials of REZPEG for atopic dermatitis are underway, each planned to enroll 510 patients. Nektar expects the first top-line results in mid-2028.
  • In Phase 2 atopic dermatitis data, about one-third of patients on a maintenance regimen achieved complete skin clearance after up to a year of treatment. An update on patients observed for a year after stopping treatment is expected in the first quarter of the following year.
  • Five stocks to consider instead of Nektar Therapeutics.

Nektar Therapeutics NASDAQ: NKTR expects to begin a Phase 3 study of rezpegaldesleukin, or REZPEG, in alopecia areata in December, while its three pivotal studies of the drug in atopic dermatitis are already underway, Head of Research and Development Jonathan Zalevsky said at the 2026 Jefferies Global Healthcare Conference in London.

The company expects the first top-line results from the atopic dermatitis program in mid-2028. Data from the alopecia areata study are expected in 2029, Zalevsky said.

REZPEG is designed to target regulatory T cells. Zalevsky said Phase 2 studies showed responses in both conditions and suggested that some patients maintained or improved their results after stopping treatment.

Atopic dermatitis follow-up

In the Phase 2 atopic dermatitis study, Zalevsky said approximately one in three patients treated for up to a year achieved complete skin clearance, measured by EASI-100, on a maintenance regimen administered every 12 weeks.

The study also includes a year of observation after treatment ends. Jefferies Senior Analyst Roger Song said the next data update, covering that off-treatment period, is expected in the first quarter of the following year.

About 125 patients completed 52 weeks of treatment and entered the observation period, including approximately 110 who received REZPEG and 15 who received placebo, Zalevsky said. Not all were EASI-75 responders at the end of treatment; the maintenance analysis will focus on the patients who had achieved a response.

Zalevsky pointed to a Dupixent withdrawal study as a benchmark. In that trial, about 50% of patients maintained an EASI-75 response over nine months after being switched to placebo injections, he said. He cautioned that the designs differ: Nektar’s study observes patients for 12 months without sham injections.

“If we reach that point at 12 months or even exceed it, we think that will be very notable,” Zalevsky said. Nektar also plans to examine other skin and itch measures, including whether patients who had not responded by the end of treatment improved during the observation period.

Phase 3 trial designs

The atopic dermatitis program includes three studies, each designed to enroll 510 patients, Zalevsky said. ZENITH AD-1 tests REZPEG alone in patients who have not previously received a biologic, while ZENITH AD-3 tests it alone in patients who have failed a biologic and/or a JAK inhibitor.

ZENITH AD-2 will compare REZPEG plus a topical corticosteroid with placebo plus a topical corticosteroid in a mixed population of treatment-naive and biologic- or JAK-experienced patients. Zalevsky said the combination design reflects the use of topical corticosteroids in different regions and that the study remains well powered.

The Phase 3 regimen calls for twice-monthly dosing for six months, followed by monthly or quarterly maintenance, he said.

Zalevsky also said Phase 2 data showed improvements in patient-reported asthma outcomes among people with both asthma and atopic dermatitis. Nektar plans to present data on rhinosinusitis and related allergies at a medical meeting in early 2027, he said.

Alopecia study planned

In severe to very severe alopecia areata, Zalevsky said Phase 2 results after 52 weeks of treatment met the benchmark Nektar had set using the JAK inhibitor Olumiant. During six months off treatment, the majority of patients maintained their regrown hair, and many continued to grow more, he said.

The planned Phase 3 trial will enroll 850 patients aged 12 and older and include both JAK-naive and JAK-experienced participants, Zalevsky said. He expects most participants to be JAK-naive. Health authorities advised that a single Phase 3 study could support a registration application, he added.

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nektar Therapeutics Right Now?

Before you consider Nektar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.

While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines